

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

The	,
,	

Application of : Esser, F., et al) Art Unit: 1626 U.S. Appln. No. : 10/827,408) Examiner: Powers, F.

Confirmation No.: 2596

U.S. Filing Date: April 19, 2004

Title of Invention: Compounds and Methods for Treating Urinary Incontinence

Attny. Docket No.: 1/1003-4-C3

Mail Stop Amendment Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

May 31, 2005

TRANSMITTAL LETTER FOR INFORMATION DISCLOSURE STATEMENT

Transmitted herewith concerning the subject application is an Information Disclosure Statement (Form 1449A/B) under 37 C.F.R. §§1.56 and 1.97, as more specifically described hereinbelow.

1.97(b). This Statement is being filed: i) within three (3) months of the filing date of a national application other than a continued prosecution application under 33 C.F.R. §1.53 (d); ii) within three (3) months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 in an international application; iii) before the mailing of a first Office action on the merits; or iv) before the mailing of a first Office action after the filing of a request for continued examination under 37 C.F.R. §1.114.

1.97(c). This Statement is being filed after the time period specified in 37 C.F.R. §1.97(b), but before the mailing date of: i) a final action under 37 C.F.R. §1.113, ii) a notice of allowance under 37 C.F.R. §1.311, or iii) an action that otherwise closes prosecution in the application. This Statement is being accompanied by:

A statement as specified in 37 C.F.R. §1.97(e) [see below]; or
The fee set forth in 37 C.F.R. §1.17(p).

		The Commissioner is hereby authorized to charge payment of the \$180.00 fee set forth in 37 C.F.R. §1.17(p) to Deposit Account No. 02-2955.
	ent as s). This Statement is being filed after the period specified in 37 C.F.R. on or before payment of the issue fee. This Statement is accompanied by a pecified in 37 C.F.R. §1.97(e) [see below] and the fee set forth in 37 C.F.R.
	1.97(e).
	counte	Each item of information contained in the instant information disclosure tent was first cited in any communication from a foreign patent office in a terpart foreign application not more than three (3) months prior to the filing of stant information disclosure statement; or
	foreign makin inform §1.56(No item of information contained in the instant information disclosure tent was cited in a communication from a foreign patent office in a counterpart in application, and, to the knowledge of the person signing this certification after g reasonable inquiry, no item of information contained in the instant nation disclosure statement was known to any individual designated in 37 C.F.R. (c) more than three (3) months prior to the filing of the instant information sure statement.
		The fee set forth in 37 C.F.R. §1.17(p).
		The Commissioner is hereby authorized to charge payment of the \$180.00 fee set forth in 37 C.F.R. §1.17(p) to Deposit Account No. 02-2955.
counte in sect	rpart ap	(d). Each item of information contained in the accompanying information tement was cited in a communication from a foreign patent office in a oplication, which communication was not received by any individual designated 6(c) more than thirty (30) days prior to the filing of the accompanying isclosure statement.

The Commissioner is hereby authorized to charge payment of any additional filing fees required under 37 C.F.R. §1.16 and any patent application processing fees under 37 C.F.R. §1.17, or credit any overpayment of same, to Deposit Account No. 02-2955.

Triplicate copies of this form are enclosed.

Respectfully submitted,

Timothy X. Witkowski Attorney for Applicant(s)

Reg. No. 40,232

Patent Department Boehringer Ingelheim Corp. 900 Ridgebury Road, P.O. Box 368 Ridgefield, CT 06877 Tel: (203) 798-4310 Certificate of Mailing

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to:

Mail Stop Amendment Commissioner For Patents P. O. Box 1450 Alexandria, VA 22313-1450

on May 31, 2005

Timothy X. Witkowski, Reg. No. 40,23

Please type a plus sign (+) inside this box 🖚

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

of Sheet

Complete if Known						
Application Number	10/827,408					
Filing Date	April 19, 2004					
First Named Inventor	Esser, F. et al					
Group Art Unit	1626					
Examiner Name	Powers, F.,					
Attorney Docket Number	1/1003-4-C3					

				U.S. PATENT DOCL	JMENTS	
Examiner Initials*	Cite No.1	U.S. Patent I	Document Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		3,081,222		Hagelman, H.A., et al	0312/1963	
		4,355,033		Ramuz, H.	10/19/1982	
		4,861,189		Fukukawa, M., et al	08/29/1989	
		5,130,441		Gluchowski, C.	07/14/1992	
		5,237,032		DeMeuse, M.T. et al,	08/17/1993	
		4,587,257		DeSantis, L.M., et al	05/06/1986	
		4,287,201		Olson, G., et al	09/01/1981	
		4,213,995		Staehle, H., et al	07/22/1980	
		4,226,773		Kynel, J.J.	10/07/1980	
		3,931,216		Franzmair, R.	01/06/1976	
		3,202,660		Zeile, K., et al	08/24/1965	
		4,861,789		Berge, et al	08/1989	
		5,237,072		Gluchowski, C.	08/1993	
		4,461,904		York, Billie M., Jr.	07/27/1984	
		5,380,742		Servnie, Mireille et al	01/10/1995	
		4,596,818		Newsome, Peter et al	06/24/1986	
		4,644,007		York, Billie M., Jr.	02/17/1987	
		-			-	
		 				

FOREIGN PATENT DOCUMENTS										
	0.1		Foreign Patent Do		Name of Patentee or	Date of Publication of	Pages, Columns, Lines, Where Relevant			
Examiner Initials*	Cite No. ¹	Office:	3 Number ⁴	Kind Code ⁵ (if known)	Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	Τe		
		EP	0 236 636	A2	Alcon Lab., Inc.	09/16/1987		$oldsymbol{ol}}}}}}}}}}}}}}}}}}$		
		wo	94/08040	A1	Synaptic Pharm. Corp.	04/14/1994				
		EP	0 070 084	A2	Beecham Group, PLC	01/19/1983				
		EP	0 117 102	A1	Beecham Group, PLC	08/29/1984				
		EΡ	0 081 923	A2	Alcon Lab., Inc.	06/22/1983				
		EP	0 081 924	A1	Alcon Lab., Inc.	06/22/1983		\perp		
		DE	28 54 659	A1	CH Boehringer Sohn	07/10/1980 .		Ш		
		DE	28 06 811		CH Boehringer Sohn	08/23/1979		\perp		
		EP	0 599 697	A1	Synthelabo	06/01/1994				
								┷		

Examiner	·	Date	
Signature		Considered	
g			

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Please type	a plus	sign	(+)	inside	this	box	->	+	
,,	•		٠,						

2

Sheet

of

3

PTO/S8/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

1/1003-4-C3

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO	С	omplete if Known
NITO DATA MICA I DICO I COLIDE	Application Number	10/824,408
INFORMATION DISCLOSURE	Filing Date	April 19, 2004
STATEMENT BY APPLICANT	First Named Inventor	Esser, F. et al
	Group Art Unit	1626
(use as many sheets as necessary)	Examiner Name	Powers, F.,

Attorney Docket Number

				U.S. PATENT DOC	JMENTS	
]	0	U.S. Paten	t Document	Name of Patentee or Applicant	Date of Publication of	Pages, Columns, Lines, Where Relevant
Examiner Initials*	Cite No. ¹	Number	Kind Code ² (if known)	of Cited Document	Cited Document MM-DD-YYYY	where Relevant Passages or Relevant Figures Appear

				FOR	EIGN PATENT DOCUMEN	TS		
Examiner	Cite		Foreign Patent Do		Name of Patentee or	Date of Publication of	Pages, Columns, Lines, Where Relevant	T
Examiner Initials	No.1	Office	3 Number ⁴	Kind Code ^s (<i>if known</i>)	Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	T6
		EP	0 416 841	A2	Hitachi Chem. Co., Ltd.	03/13/1991		
		EP	0 682 028	A1	Synthelabo	11/15/1995		1
		DE	2 316 377		Lentia GmbH	10/17/1974		
		DE	1 929 950		C.H. Boehringer Sohn	03/05/1970		
		ļ						┷
		ļ						+
		-				 		┿
		-						+-
		 	-			+		+
		L			<u> </u>			

Examiner	Date	
Signature	Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for	form 1449B/PTO			Complete if Known		
				Application Number	10/827,408	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Filing Date	April 19, 2004	-
				First Named Inventor	Esser, F., et al	
				Art Unit	1626	
(Use as many sheets as necessary)				Examiner Name	Fiona Powers	
Sheet	3	of	3	Attorney Docket Number	1/1003-4-C3	

NON PATENT LITERATURE DOCUMENTS								
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.						
		NORDLING, J., et al; "Sympathetic Influence of Striated Urethral Sphincter in Urinary Incontinence", Prog. Clin. Biol. Res., Vol. 78, pages 101-103; 1981						
		RANDALL, W.C., et al; "Multiple Central Alpha 1 Adrenoceptors of Avian and Mammalian Species"; Biochem. Pharmacol., Vol. 32. No. 12. Pgs 1933-1940; 1983	************					
		KONTANI, H., et al; "Effects of Adrenergic Agonists on an Experimental Urinary Incontinence Model in Anesthetized Rabbits"; Jpn. J. Pharmacol., Vol. 58, No. 4 pages 339-346; 1992						
	• • • • • • • • • • • • • • • • • • • •	VAN SAVAGE, J.G., et al; "Effects of Alpha-Adrenergic Agonist on Neobladder Water and Elelctrolyty Transport", Urology, Vol. 43, No. 3, pages 324-327, 1994	•••••					

i	1	<u>'</u>	ı .					

Examiner	Date	
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete his form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.